Feb 04, 2025
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 30, 2025
Syndax Announces Participation in February Investor Conferences
Jan 13, 2025
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
Jan 07, 2025
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Jan 03, 2025
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 09, 2024
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
Dec 03, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 27, 2024
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
Nov 15, 2024
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Nov 12, 2024
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
Nov 05, 2024
Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo(TM) (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting
Nov 05, 2024
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
Nov 05, 2024
Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024
Nov 05, 2024
Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 04, 2024
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo(TM)
Nov 01, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 29, 2024
Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024
Oct 04, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 18, 2024
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo(TM) (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
Aug 12, 2024
Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia